Cite
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
MLA
Abraham, Jame, et al. “Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer: NSABP Foundation Study FB-9.” Breast Cancer Research and Treatment, vol. 152, no. 2, July 2015, pp. 399–405. EBSCOhost, https://doi.org/10.1007/s10549-015-3466-4.
APA
Abraham, J., Robidoux, A., Tan, A. R., Limentani, S., Sturtz, K., Shalaby, I., Alcorn, H., Buyse, M. E., Wolmark, N., & Jacobs, S. A. (2015). Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Research and Treatment, 152(2), 399–405. https://doi.org/10.1007/s10549-015-3466-4
Chicago
Abraham, Jame, André Robidoux, Antoinette R Tan, Steven Limentani, Keren Sturtz, Ibrahim Shalaby, Hope Alcorn, Marc E Buyse, Norman Wolmark, and Samuel A Jacobs. 2015. “Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer: NSABP Foundation Study FB-9.” Breast Cancer Research and Treatment 152 (2): 399–405. doi:10.1007/s10549-015-3466-4.